Foley Todd 4

Accession 0001473930-26-000005

CIK 0002035832other

View on SEC.gov Company Profile

Filed

Jan 13, 7:00 PM ET

Accepted

Jan 14, 6:20 PM ET

Size

18.8 KB

Accession

0001473930-26-000005

Insider Transaction Report

Form 4

Period: 2026-01-12

Aktis Oncology, Inc.AKTS

Foley Todd

Director10% Owner

Transactions

Conversion
Common Stock
[F1][F2][F3][F4]
2026-01-12+597,391→ 597,391 total(indirect: See Footnote)
Conversion
Common Stock
[F5][F2][F3][F6]
2026-01-12+2,688,270→ 3,285,661 total(indirect: See Footnote)
Conversion
Common Stock
[F7][F2][F3][F8]
2026-01-12+716,872→ 4,002,533 total(indirect: See Footnote)
Purchase
Common Stock
[F9][F3][F10]
2026-01-12$18.00/sh+232,870$4,191,660→ 4,235,403 total(indirect: See Footnote)
Conversion
Series Seed Redeemable Convertible Preferred Stock
[F2][F1][F3]
2026-01-12−2,272,727→ 0 total(indirect: See Footnote)
→ Common Stock (597,391 underlying)
Conversion
Series A Redeemable Convertible Preferred Stock
[F2][F3][F5]
2026-01-12−10,227,273→ 0 total(indirect: See Footnote)
→ Common Stock (2,688,270 underlying)
Conversion
Series B Redeemable Convertible Preferred Stock
[F2][F3][F7]
2026-01-12−2,727,273→ 0 total(indirect: See Footnote)
→ Common Stock (716,872 underlying)

Footnotes (10)

[F1]The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC.
[F10]The shares are held as follows: 3,950,528 by BV 2018, 206,964 by BV 2018(B) and 77,911 by AM BV2018.
[F2]Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.
[F3]The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
[F4]The shares are held as follows: 556,810 by BV 2018, 29,593 by BV 2018(B) and 10,988 by AM BV2018.
[F5]The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018.
[F6]The shares are held as follows: 3,062,458 by BV 2018, 162,763 by BV 2018(B) and 60,440 by AM BV2018.
[F7]The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018.
[F8]The shares are held as follows: 3,730,631 by BV 2018, 198,275 by BV 2018(B) and 73,627 by AM BV2018.
[F9]The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B) and 4,284 by AM BV2018.

Signature

/sTodd Foley|2026-01-14

Documents

1 file

4
form4-01142026_110116.xmlPrimary

Issuer

Aktis Oncology, Inc.

CIK 0002035832

→

Entity typeother

Related Parties

filerCIK 0001473930

Filing Metadata

Form type: 4
Filed: Jan 13, 7:00 PM ET
Accepted: Jan 14, 6:20 PM ET
Size: 18.8 KB

View on SEC.gov